Ionis Pharmaceuticals, Inc. Q4 2025 Earnings Call Summary

Successfully transitioned into a fully integrated commercial-stage company following the first two independent launches of TRYNGOLZA and DAWNZERA. Performance attribution for TRYNGOLZA was driven by a compelling clinical profile and strong execution, exceeding expectations with $108 million in full-year revenue. Achieved breakthrough Phase III results for olezarsen in severe hypertriglyceridemia, demonstrating an unprecedented 85% reduction in acute pancreatitis events. Strategic positioning in neur ...